Cargando…

Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review

OBJECTIVE: This article systematically reviewed the methodological quality of modelling approaches for economic evaluations of the treatment of motor symptoms in Parkinson’s disease in studies published after 2010. METHODS: A systematic literature search was undertaken using PubMed, EconLit, the Coc...

Descripción completa

Detalles Bibliográficos
Autores principales: Dams, Judith, Zapp, Johann-Jacob, König, Hans-Helmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492764/
https://www.ncbi.nlm.nih.gov/pubmed/37344724
http://dx.doi.org/10.1007/s40273-023-01289-0
_version_ 1785104326261211136
author Dams, Judith
Zapp, Johann-Jacob
König, Hans-Helmut
author_facet Dams, Judith
Zapp, Johann-Jacob
König, Hans-Helmut
author_sort Dams, Judith
collection PubMed
description OBJECTIVE: This article systematically reviewed the methodological quality of modelling approaches for economic evaluations of the treatment of motor symptoms in Parkinson’s disease in studies published after 2010. METHODS: A systematic literature search was undertaken using PubMed, EconLit, the Cochrane Database of Systematic Reviews, National Health Service Economic Evaluation Database and Health Technology Assessment databases of the UK National Health Service Centre for Review and Dissemination (March 2010 to July 2022). Quality was assessed using a checklist from the German Scientific Working Group. RESULTS: A total of 20 studies were evaluated, with the majority based on Markov models (n = 18). Studies assessed the cost effectiveness of medical (n = 12) or surgical (n = 8) treatment, and included costs from a payer or healthcare provider’s perspective (n = 17). Furthermore, all studies included quality-adjusted life-years as an effect measure. In the quality assessment of the literature, a mean score of 42.1 points (out of 56 points) on the checklist of the German Scientific Working Group was achieved. Seventeen studies concluded the intervention under study was (likely) cost effective. No intervention was classified as cost ineffective. CONCLUSIONS: The quality of economic evaluation models in Parkinson’s disease has improved in terms of calculating cost and transition parameters, as well as carrying out probabilistic sensitivity analyses, compared with the published literature of previous systematic reviews up to 2010. However, there is still potential for further development in terms of the integration of non-motor complications and treatment changes, the transparent presentation of parameter estimates, as well as conducting sensitivity analyses and validations to support the interpretation of results. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-023-01289-0.
format Online
Article
Text
id pubmed-10492764
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-104927642023-09-11 Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review Dams, Judith Zapp, Johann-Jacob König, Hans-Helmut Pharmacoeconomics Systematic Review OBJECTIVE: This article systematically reviewed the methodological quality of modelling approaches for economic evaluations of the treatment of motor symptoms in Parkinson’s disease in studies published after 2010. METHODS: A systematic literature search was undertaken using PubMed, EconLit, the Cochrane Database of Systematic Reviews, National Health Service Economic Evaluation Database and Health Technology Assessment databases of the UK National Health Service Centre for Review and Dissemination (March 2010 to July 2022). Quality was assessed using a checklist from the German Scientific Working Group. RESULTS: A total of 20 studies were evaluated, with the majority based on Markov models (n = 18). Studies assessed the cost effectiveness of medical (n = 12) or surgical (n = 8) treatment, and included costs from a payer or healthcare provider’s perspective (n = 17). Furthermore, all studies included quality-adjusted life-years as an effect measure. In the quality assessment of the literature, a mean score of 42.1 points (out of 56 points) on the checklist of the German Scientific Working Group was achieved. Seventeen studies concluded the intervention under study was (likely) cost effective. No intervention was classified as cost ineffective. CONCLUSIONS: The quality of economic evaluation models in Parkinson’s disease has improved in terms of calculating cost and transition parameters, as well as carrying out probabilistic sensitivity analyses, compared with the published literature of previous systematic reviews up to 2010. However, there is still potential for further development in terms of the integration of non-motor complications and treatment changes, the transparent presentation of parameter estimates, as well as conducting sensitivity analyses and validations to support the interpretation of results. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-023-01289-0. Springer International Publishing 2023-06-21 2023 /pmc/articles/PMC10492764/ /pubmed/37344724 http://dx.doi.org/10.1007/s40273-023-01289-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Systematic Review
Dams, Judith
Zapp, Johann-Jacob
König, Hans-Helmut
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review
title Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review
title_full Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review
title_fullStr Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review
title_full_unstemmed Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review
title_short Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review
title_sort modelling the cost effectiveness of treatments for parkinson’s disease: an updated methodological review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492764/
https://www.ncbi.nlm.nih.gov/pubmed/37344724
http://dx.doi.org/10.1007/s40273-023-01289-0
work_keys_str_mv AT damsjudith modellingthecosteffectivenessoftreatmentsforparkinsonsdiseaseanupdatedmethodologicalreview
AT zappjohannjacob modellingthecosteffectivenessoftreatmentsforparkinsonsdiseaseanupdatedmethodologicalreview
AT konighanshelmut modellingthecosteffectivenessoftreatmentsforparkinsonsdiseaseanupdatedmethodologicalreview